• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Prev Vet Med . Cost-benefit analysis of swine influenza a vaccination in wean-to-finish production setting in the United States

tetano

Editor, Senior Moderator
Prev Vet Med


. 2026 Feb 6:249:106806.
doi: 10.1016/j.prevetmed.2026.106806. Online ahead of print.
Cost-benefit analysis of swine influenza a vaccination in wean-to-finish production setting in the United States

Dana C Pittman Ratterree[SUP] 1 [/SUP], Robert Ohsfeldt[SUP] 2 [/SUP], Sapna Chitlapilly Dass[SUP] 3 [/SUP], Martial L Ndeffo-Mbah[SUP] 4 [/SUP]


Affiliations
Abstract

Swine influenza virus A (SIV-A) is endemic in hog farms globally, causing significant economic losses to the swine industry. While vaccination is a recommended control strategy, its economic value in specific production phases remains under-evaluated. This study investigated the economic viability of SIV-A vaccination in a U.S. wean-to-finish commercial farm using a stochastic epidemic model. A cost-benefit analysis was performed to estimate the Benefit-Cost Ratio (BCR), Net Present Value (NPV), and Return on Investment (ROI) of swine vaccination. In the absence of vaccination, the model predicted a high within-farm attack rate of approximately 82.5 % (95 % Confidence Interval (CI): 81 % - 0.84 %). Economic analysis showed that the profitability of SIV-A vaccination was highly dependent on vaccine efficacy. Vaccine efficacy below 70 % was shown to be not economically viable, yielding negative NPV and BCR below 1. Conversely, vaccination with ≥ 80 % efficacy was profitable, with BCRs ranging from 1.54 (95 % CI: 1.538, 1.54) to 4.09 (95 % CI: 4.082, 4.092) and net profits varying from US$0.90 ( 95 % CI: US$0.79, US$1.02) per pig up to US$3.41 (95 %CI: US$3.40, US$3.41) per pig. Vaccination against SIV-A in wean-to-finish settings was shown to be an economically favorable intervention when the vaccine is highly efficacious against the circulating SIV-A subtype. Sensitivity analysis indicated that vaccine efficacy, the cost of vaccination, and influenza-induced mortality rates were the most critical drivers determining the economic success of the program.

Keywords: Cost-Benefit Analysis; Cost-Benefit Ratio; Mathematical Modeling; Pig; Swine Influenza A; Vaccination; Wean-to-Finish farm.

 
Back
Top Bottom